Higher Cerebrospinal Fluid Soluble Urokinase-type Plasminogen Activator Receptor, But Not Interferon γ-inducible Protein 10, Correlate With Higher Working Memory Deficits.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
received:
21
06
2021
accepted:
18
01
2022
pubmed:
29
1
2022
medline:
9
4
2022
entrez:
28
1
2022
Statut:
ppublish
Résumé
We hypothesized that the induction of monocyte activation biomarkers, especially soluble urokinase-type plasminogen activator receptor (suPAR) and interferon γ-inducible protein 10 (IP-10), is lower in HIV-1C than HIV-1B, owing to a defective Tat cysteine dimotif (C30S). A total of 68 paired cerebrospinal fluid (CSF) and blood samples from people with HIV (PWH), free of CNS opportunistic infections, from a Southern Brazil outpatient HIV clinic were evaluated such as HIV-1B subtype (n = 27), HIV-1C (n = 26), other (n = 15), and 19 HIV-negative controls. The levels of suPAR, IP-10, neopterin, and β2 microglobulin (β2m) in the CSF and serum were quantified using different immunoassays. Overall, in PWH, increases in CSF suPAR, CSF/serum suPAR, and CSF/serum β2m correlated with worse working memory deficits (r = 0.303, 0.353, and 0.289, respectively, all P < 0.05). The medians of IP-10, suPAR, neopterin, and β2m in CSF and serum and the CSF/serum ratio and suPAR index were comparable between the HIV-1B and HIV-1C subtypes. CSF IP-10 and neopterin and serum IP-10 and suPAR levels were higher in PWH than the HIV-negative controls (P = 0.015, P = 0.001, P < 0.0001, and P < 0.001, respectively). The serum β2m level was higher in HIV-associated dementia than neuropsychologically normal or asymptomatic (P = 0.024). We observed that higher levels of CSF suPAR and the suPAR quotient correlated with worse working memory deficit. Elevated levels of monocyte activation were similar in both HIV-1 B and C subtypes, providing no evidence of reduced neuropathogenicity of HIV-1 subtype C Tat compared with subtype B.
Sections du résumé
BACKGROUND
We hypothesized that the induction of monocyte activation biomarkers, especially soluble urokinase-type plasminogen activator receptor (suPAR) and interferon γ-inducible protein 10 (IP-10), is lower in HIV-1C than HIV-1B, owing to a defective Tat cysteine dimotif (C30S).
METHODS
A total of 68 paired cerebrospinal fluid (CSF) and blood samples from people with HIV (PWH), free of CNS opportunistic infections, from a Southern Brazil outpatient HIV clinic were evaluated such as HIV-1B subtype (n = 27), HIV-1C (n = 26), other (n = 15), and 19 HIV-negative controls. The levels of suPAR, IP-10, neopterin, and β2 microglobulin (β2m) in the CSF and serum were quantified using different immunoassays.
RESULTS
Overall, in PWH, increases in CSF suPAR, CSF/serum suPAR, and CSF/serum β2m correlated with worse working memory deficits (r = 0.303, 0.353, and 0.289, respectively, all P < 0.05). The medians of IP-10, suPAR, neopterin, and β2m in CSF and serum and the CSF/serum ratio and suPAR index were comparable between the HIV-1B and HIV-1C subtypes. CSF IP-10 and neopterin and serum IP-10 and suPAR levels were higher in PWH than the HIV-negative controls (P = 0.015, P = 0.001, P < 0.0001, and P < 0.001, respectively). The serum β2m level was higher in HIV-associated dementia than neuropsychologically normal or asymptomatic (P = 0.024).
DISCUSSION
We observed that higher levels of CSF suPAR and the suPAR quotient correlated with worse working memory deficit. Elevated levels of monocyte activation were similar in both HIV-1 B and C subtypes, providing no evidence of reduced neuropathogenicity of HIV-1 subtype C Tat compared with subtype B.
Identifiants
pubmed: 35090158
doi: 10.1097/QAI.0000000000002924
pii: 00126334-202205010-00015
pmc: PMC8986587
mid: NIHMS1774517
doi:
Substances chimiques
Biomarkers
0
CXCL10 protein, human
0
Chemokine CXCL10
0
Receptors, Urokinase Plasminogen Activator
0
Neopterin
670-65-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
106-114Subventions
Organisme : NIDA NIH HHS
ID : K24 DA040550
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI036214
Pays : United States
Organisme : NIMH NIH HHS
ID : P30 MH062512
Pays : United States
Organisme : NIMH NIH HHS
ID : R21 MH076651
Pays : United States
Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Ruhanya V, Jacobs GB, Naidoo S, et al. Impact of plasma IP-10/CXCL10 and RANTES/CCL5 levels on neurocognitive function in HIV treatment-naive patients. AIDS Res Hum Retroviruses. 2021;37:657–665.
Enting RH, Foudraine NA, Lange JM, et al. Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine. J Neuroimmunol. 2000;102:216–221.
Sidenius N, Nebuloni M, Sala S, et al. Expression of the urokinase plasminogen activator and its receptor in HIV-1- associated central nervous system disease. J Neuroimmunol. 2004;157:133–139.
Cinque P, Nebuloni M, Santovito ML, et al. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. Ann Neurol. 2004;55:687–694.
Cinque P, Bestetti A, Marenzi R, et al. Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol. 2005;168:154–163.
Gianella S, Letendre SL, Iudicello J, et al. Plasma (1→3)-β-D-glucan and suPAR levels correlate with neurocognitive performance in people living with HIV on antiretroviral therapy: a CHARTER analysis. J Neurovirol. 2019;25:837–843.
Meeker RB, Poulton W, Markovic-Plese S, et al. Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection. J Neurovirol. 2011;17:258–273.
Desmedt S, Desmedt V, Delanghe JR, et al. The intriguing role of soluble urokinase receptor in inflammatory diseases. Crit Rev Clin Lab Sc. 2017;54:117–133.
Vassalli JD, Wohlwend A, Belin D. Urokinase-catalyzed plasminogen activation at the monocyte/macrophage cell surface: a localized and regulated proteolytic system. Curr Top Microbiol Immunol. 1992;181:65–86.
Nykjaer A, Moller B, Todd RF III, et al. Urokinase receptor. An activation antigen in human T lymphocytes. J Immunol. 1994;152:505–516.
Marcos-Contreras OA, Lizarrondo SM, Bardou I, et al. Hyperfibrinolysis increases blood-brain barrier permeability by a plasmin- and bradykinin-dependent mechanism. Blood. 2016;128:2423–2434.
Lane BR, King SR, Bock PJ, et al. The C-X-C chemokine IP-10 stimulates HIV-1 replication. Virology. 2003;307:122–134.
Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev. 1997;8:207–219.
Taub DD, Lloyd AR, Conlon K, et al. Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med. 1993;177:1809–1814.
Vanguri P, Farber JM. IFN and virus-inducible expression of an immediate early gene, crg-2/IP-10, and a delayed gene,I-A alpha in astrocytes and microglia. J Immunol. 1994;152:1411–1418.
Cheng G, Nazar AS, Shin HS, et al. IP-10gene transcription by virus in astrocytes requires coopera-tion of ISRE with adjacent kappa B site but not IRF-1 or viral transcription. J Interferon Cytokine Res. 1998;18:987–997.
Shen Q, Zhang R, Bhat NR. MAP kinase regulation ofIP10/CXCL10 chemokine gene expression in microglial cells. Brain Res. 2006;1086:9–16.
Park C, Lee S, Cho IH, et al. TLR3-mediated signal induces proinflammatory cytokine and chemokine gene expression in astrocytes: differential signaling mechanisms of TLR3-induced IP-10 and IL-8 gene expression. Glia. 2006;53:248–256.
Hua LL, Lee SC. Distinct patterns of stimulus-inducible chemokine mRNA accumulation in human fetal astrocytes and microglia. Glia. 2000;30:74–81.
Harvey CE, Post JJ, Palladinetti P, et al. Expression of the chemokine IP-10 (CXCL10) by hepatocytes in chronic hepatitis C virus infection correlates with histological severity and lobular inflammation. J Leukoc Biol. 2003;74:360–369.
Kutsch O, Oh J, Nath A, et al. Induction of the chemokines interleukin-8 and IP-10 by human immunodeficiency virus type 1 tat in astrocytes. J Virol. 2000;74:9214–9221.
Chen P, Mayne M, Power C, et al. The Tat protein of HIV-1 induces tumor necrosis factor-alpha production. Implications for HIV-1-associated neurological diseases. J Biol Chem. 1997;272:22385–22388.
Albini A, Benelli R, Giunciuglio D, et al. Identification of a novel domain of HIV tat involved in monocyte chemotaxis. J Biol Chem. 1998;273:15895–15900.
Ranga U, Shankarappa R, Siddappa NB, et al. Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J Virol. 2004;78:2586–2590.
Williams ME, Zulu SS, Stein DJ, et al. Signatures of HIV-1 subtype B and C Tat proteins and their effects in the neuropathogenesis of HIV-associated neurocognitive impairments. Neurobiol Dis. 2020;136:104701.
Campbell GR, Watkins JD, Singh KK, et al. Human immunodeficiency virus type 1 subtype C tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes. J Virol. 2007;81:5919–5928.
Gandhi N, Saiyed Z, Thangavel S, et al. Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and antiinflammatory cytokines by primary monocytes. AIDS Res Hum Retrovir. 2009;25:691–699.
Wong JK, Campbell GR, Spector SA. Differential induction of interleukin-10 in monocytes by HIV-1 clade B and clade C Tat proteins. J Biol Chem. 2010;285:18319–18325.
de Almeida SM, Rotta I, Vidal LRR, et al. HIV-1C and HIV-1B Tat protein polymorphism in Southern Brazil. J Neurovirol . 2021;27:126–136.
Andersen O, Eugen-Olsen J, Kofoed K, et al. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J Med Virol. 2008;80:209–216.
Caudie C, Bancel J, Dupont M, et al. CSF levels and diagnostic utility of cerebrospinal fluid beta2-microglobulin. Ann Biol Clin. 2005;63:631–637.
Reiber H, Padilla-Docal B, Jensenius JC, et al. Mannan-binding lectin in cerebrospinal fluid: a leptomeningeal protein. Fluids Barriers CNS. 2012;9:17.
de Almeida SM, Ribeiro CE, de Pereira AP, et al. Neurocognitive impairment in HIV-1 clade C- versus B-infected individuals in Southern Brazil. J Neurovirol. 2013;19:550–556.
Heaton RK, Miller SW, Taylor MJ, et al. Revised Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults. Lutz, FL: Psychological Assessment Resources, Inc; 2004.
Chelune GJ, Heaton RK, Lehman RA. Neuropsychological and personality correlates of patients complaints of disability. In: Goldstein GJ, Tarter RE, eds. Advances in Clinical Neuropsychology. New York, NY: Plenum; 1986:95–126.
Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–1799.
Carey CL, Woods SP, Rippeth JD, et al. Initial validation of a screening battery for the detection of HIV-associated cognitive impairment. Clin Neuropsychol. 2004;18:234–248.
Cowan N. What are the differences between long-term, short-term, and working memory? Prog Brain Res. 2008;169:323–338.
Brew BJ, Bhalla RB, Fleisher M, et al. Cerebrospinal fluid beta 2 microglobulin in patients infected with human immunodeficiency virus. Neurology. 1989;39:830–834.
Mcarthur JC, Nance-Sproson TE, Griffin DE, et al. The diagnostic utility of elevation in cerebrospinal fluid beta 2-microglobulin in HIV-1 dementia. Multicenter AIDS cohort study. Neurology. 1992;42:1707–1712.
de Almeida SM, Rotta I, Jiang Y, et al. Biomarkers of chemotaxis and inflammation in cerebrospinal fluid and serum in individuals with HIV-1 subtype C versus B. J Neurovirol. 2016;22:715–724.
de Almeida SM, Rotta I, de Pereira AP, et al. Cerebrospinal fluid pleocytosis as a predictive factor for CSF and plasma HIV RNA discordance and escape. J Neurovirol. 2020;26:241–251.
de Almeida SM, Rotta I, Tang B, et al. IgG intrathecal synthesis in HIV-associated neurocognitive disorder (HAND) according to the HIV-1 subtypes and pattern of HIV RNA in CNS and plasma compartments. J Neuroimmunol. 2021;355:577542.
de Almeida SM, Ribeiro CE, Rotta I, et al. Biomarkers of neuronal injury and amyloid metabolism in the cerebrospinal fluid of patients infected with HIV-1 subtypes B and C. J Neurovirol. 2018;24:28–40.
de Almeida SM, Ribeiro CE, Rotta I, et al. Blood amyloid-β protein isoforms are affected by HIV-1 in a subtype-dependent pattern. J Neurovirol. 2020;26:3–13.
Cunningham O, Campion S, Perry VH, et al. Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation. Glia. 2009;57:1802–1814.
Lund LR, Romer J, Ronne E, et al. Urokinasereceptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor b 1 in human A549 lung carcinoma cells. EMBO J. 1991;10:3399–3407.
Gyetko MR, Sud S, Kendall T, et al. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection. J Immunol. 2000;165:1513–1519.
Washington RA, Becher B, Balabanov R, et al. Expression of the activation marker urokinase plasminogen-activator receptor in cultured human central nervous system microglia. J Neurosci Res. 1996;45:392–399.
Blasi F, Carmeliet P. uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol. 2002;3:932–943.
Gangur V, Simons FE, Hayglass KT. Human IP-10 selectively promotes dominance of polyclonally activatedand environmental antigen-driven IFN-gamma over IL-4 responses. FASEB J. 1998;12:705–713.
Williams R, Yao H, Dhillon NK, et al. HIV-1 Tat co-operates with IFN- γ and TNF- α to increase CXCL10 in human astrocytes. PLoS One. 2009;4:e5709.
Wang XQ, Palmer S. Single-molecule techniques to quantify and genetically characterise persistent HIV. Retrovirol. 2018;15:3.
Gantner P, Pagliuzza A, Pardons M, et al. Single-cell TCR sequencing reveals phenotypically diverse clonally expanded cells harboring inducible HIV proviruses during ART. Nat Commun. 2020;11:4089.
Corley MJ, Farhadian SF. Emerging single-cell approaches to understand HIV in the central nervous system. Curr HIV/AIDS Rep. 2021:1–8. doi: 10.1007/s11904-021-00586-7.
doi: 10.1007/s11904-021-00586-7